Testing RC48 for ovarian cancer returning after platinum treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemo, and you've had between 1 and 4 previous treatments.
- Your tumor has a specific protein called HER2 (levels 1+, 2+, or 3+). You need to provide a tissue sample to confirm this.
- You have not had prior treatment with a HER2-targeting drug (like trastuzumab or other ADC drugs).
- You are in generally good health (able to do daily activities) and have adequate organ function (kidneys, liver, blood).
- You have at least one measurable tumor (by CT or MRI), and you can get pregnant so you need a negative pregnancy test and birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called RC48, alone or with envafolimab, for men with a specific type of advanced prostate cancer that has not responded to standard treatments. It aims to see if this combination can shrink tumors or slow disease progression.
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a combination of the targeted therapy RC48 and the chemotherapy drug carboplatin given before surgery for people with advanced ovarian cancer that has a specific protein (HER2). The goal is to see if this treatment can shrink the tumor enough to allow for complete removal during surgery.
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
Hear when a new Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.